Sown: 19 April 2024
Harvested: 12 December 2024
Rotation position: 2023 Wheat
Soil type: Clay
FAR code: FAR VIC II C24-44

The Germplasm Evaluation Network (GEN) is a FAR Australia ‘Industry Innovations’ initiative that tests crop performance across FAR Australia’s national network of Crop Technology Centres. GEN sites test crop performance with and without fungicide. FAR Australia provides the control varieties and breeders enter their chosen lines for evaluation.

Key Points:
• A rainfall event in early April produced a good seedbed for emergence in the trial, but drier conditions later in the autumn and the following spring reduced yield potential.

• Seed yields ranged 2.32 – 3.30t/ha depending on variety and fungicide application with significant differences in variety performance whether the crop was treated or untreated with fungicide.

• As shown in previous hyper yielding crops evaluations the mid-season variety 45Y95CL performed very strongly being significantly higher yielding than all other varieties tested when the two management approaches were averaged.

• Slightly lower yielding was a raft of other hybrids that performed strongly including coded line AN23LR014, the mid-season TruFlex® line Nuseed Eagle TF and the early-mid hybrid Hyola Regiment XC that combines TruFlex® technology and an ability to apply Imidazolinone (IMI) herbicides.

• The season did not lend itself to disease infection and neither blackleg or sclerotinia had a bearing on seed yield, test weight or oil content.

• There was a significant interaction (p=0.029) between cultivar and fungicide application suggesting that varieties responded differently to fungicide application, however whether the small yield effects were positive or negative they did not appear to be linked to disease infection.

• Hyola Regiment XC (45.2%) gave significantly higher oil contents than all other varieties except Nuseed Eagle TF (44.6%). Oil content for 45Y95CL was 43.2%.

• Pioneer PY525G Optimum GLY registered trademark herbicide technology and RGT65-074CL performed less strongly in this trial.

Please click READ MORE  to access the full document.